Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H3.Y is a primate-specific variant of histone H3, evolutionarily derived from H3.3, and is a core component of nucleosomes in chromatin[1][2][6]. H3.Y-containing nucleosomes preferentially accumulate around transcription start sites and are characterized by more flexible DNA ends and reduced binding of linker histone H1 compared to canonical H3.3, resulting in a potentially more relaxed chromatin structure that facilitates transcription factor access and gene expression regulation[1][2][6]. It is encoded by the H3Y1 gene (GeneCards ID: H3Y1, UniProtKB: P0DPK2, HGNC: 43735) and is localized to the nucleoplasm as part of the nucleosome complex[2][4][6]. H3.Y is not classified as a conventional therapeutic target, such as a receptor or enzyme, but rather as a structural protein involved in the regulation of chromatin and gene expression. Disease associations have been identified with certain muscular dystrophies[2]. No known drugs directly interact with histone H3.Y and it does not currently serve as a biomarker or direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H3.Y (H3Y1).